Deng Hongkui
Deng Hongkui(Chinese:Đặng hoành khôi) is a Chineseimmunologistandstem cellresearcher. He is aChang gian g Professor,the Boya Chair Professor, and Director of the Institute of Stem Cell Research atPeking University.He was awarded US$1.9 million by theBill & Melinda Gates Foundationfor his research on vaccines forHIVandhepatitis C.In 2017, he andChen Huengineered resistance toHIVin mice usingCRISPR gene editing,and for the first time used the technique on an AIDS patient.
Biography
[edit]Deng Hongkui enteredWuhan Universityin 1980, where he earned his B.Sc. in 1984. He then studied atShanghai Second Medical Collegeand earned his master's degree in 1987. In 1990, he moved to the United States to study at theUniversity of California, Los Angeles,where he earned his Ph.D. in 1995,[1][2]under the supervision of Eli Sercarz.[3]From 1995 to 1998 he was an Aaron Diamond Postdoctoral Fellow at theNew York University School of Medicine,[1]where he conducted research underDan Littman.[3]From 1998 to 2001, he worked as research director of ViaCell, astem cellbiotech company based inBoston.[4]
In 2001, Deng was awarded the prestigiousChang gian g Professorshipby the Chinese government, and returned to China to work atPeking University.[1][4]He initially worked on treatingdiabetesusinghuman embryonic stem cells.[4]During theSARS outbreak,he conducted research onSARStreatment and vaccine.[5]In 2006, he was awarded US$1.9 million by theGrand Challenges In Global Healthinitiative of theBill & Melinda Gates Foundation,for his research on vaccines forHIVandhepatitis C.[4]He became Director of Peking University's Institute of Stem Cell Research in 2013 and was appointed the Boya Chair Professor in 2016.[2][6]
In 2017, Deng and his collaborator,Chen Huof the307 Hospital,usedCRISPR gene editingto transplant humanhematopoietic stem cellswith the editedCCR5gene to mice, and conferredHIVresistance to the animals.[7]They subsequently used the technique to treat an AIDS patient who suffered fromacute lymphoblastic leukemia(ALL). It was the first time CRISPR was used on a human HIV patient.[8][6]19 months later, the patient's ALL was in complete remission.[8]Their research demonstrated the safety of CRISPR for humans, although the therapy was not effective for curing AIDS as only 5% to 8% of the patient'sbone marrowcells carried the edited CCR5 gene, much lower than the ideal 100%.[4]Their findings were published inThe New England Journal of Medicinein September 2019.[9]
References
[edit]- ^abc"Hongkui Deng".Peking University.Archivedfrom the original on 16 December 2017.Retrieved23 September2019.
- ^ab"Đặng hoành khôi".Peking University School of Life Sciences.Archivedfrom the original on 28 April 2019.Retrieved23 September2019.
- ^ab"Mentoring the Next Generation: Hongkui Deng".Cell Stem Cell.22(5): 621–622. 3 May 2018.doi:10.1016/j.stem.2018.03.021.ISSN1934-5909.
- ^abcdeBegley, Sharon (11 September 2019)."In a CRISPR first, therapy aiming to cure HIV patient appears safe".STAT.Archivedfrom the original on 13 September 2019.Retrieved22 September2019.
- ^Cong Lanlan tùng Lan Lan (24 June 2003)."Bắc đại sinh mệnh viện khoa học giáo thụ Đặng hoành khôi: Bắc đại gia tăng kháng phi nghiên cứu".People's Daily.Archivedfrom the original on 23 September 2019.Retrieved23 September2019.
- ^ab"CRISPR biên tập tế bào gốc trị liệu HIV cùng cấp tính tuyến dịch lim-pha tế bào bệnh bạch cầu người bệnh".Sciencenet.12 September 2019.Archivedfrom the original on 22 September 2019.Retrieved22 September2019.
- ^Azvolinsky, Anna (3 August 2017)."Resistance to HIV Engineered Via CRISPR".The Scientist Magazine.Archivedfrom the original on 8 September 2018.Retrieved22 September2019.
- ^abJulie Zaugg and Serenitie Wang (13 September 2019)."Chinese scientists use CRISPR tool on HIV patient for the first time".CNN.Archivedfrom the original on 13 September 2019.Retrieved22 September2019.
- ^Xu, Lei; Wang, Jun; Liu, Yulin; Xie, Liangfu; Su, Bin; Mou, Danlei; Wang, Longteng; Liu, Tingting; Wang, Xiaobao (11 September 2019)."CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia".New England Journal of Medicine.381(13): 1240–1247.doi:10.1056/NEJMoa1817426.PMID31509667.
